|
|
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells |
Yongping Zhang1, Xingying Zhang2,3, Chen Cheng2,4, Wei Mu2,3, Xiaojuan Liu2, Na Li2, Xiaofei Wei6, Xiang Liu2, Changqing Xia1,5(), Haoyi Wang2,3() |
1. Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China 2. State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing100190, China 3. University of Chinese Academy of Sciences, Beijing 100049, China 4. Graduate School, University of Science and Technology of China, Hefei 230026, China 5. Department of Pathology, Immunology and Laboratory Medicine, University of Florida, FL 32611, USA 6. Beijing Cord Blood Bank, Beijing100176, China |
|
|
Abstract T cells engineered with chimeric antigen receptor (CAR) have been successfully applied to treat advanced refractory B cell malignancy. However, many challenges remain in extending its application toward the treatment of solid tumors. The immunosuppressive nature of tumor microenvironment is considered one of the key factors limiting CAR-T efficacy. One negative regulator of T cell activity is lymphocyte activation gene-3 (LAG-3). We successfully generated LAG-3 knockout T and CAR-T cells with high efficiency using CRISPR-Cas9 mediated gene editing and found that the viability and immune phenotype were not dramatically changed during in vitro culture. LAG-3 knockout CAR-T cells displayed robust antigen-specific antitumor activity in cell culture and in murine xenograft model, which is comparable to standard CAR-T cells. Our study demonstrates an efficient approach to silence immune checkpoint in CAR-T cells via gene editing.
|
Keywords
CAR-T
CRISPR-Cas9
LAG-3
|
Corresponding Author(s):
Changqing Xia,Haoyi Wang
|
Just Accepted Date: 10 May 2017
Online First Date: 19 June 2017
Issue Date: 04 December 2017
|
|
1 |
Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J 2014; 20(2): 151–155
https://doi.org/10.1097/PPO.0000000000000032
pmid: 24667962
|
2 |
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6(224): 224ra25
https://doi.org/10.1126/scitranslmed.3008226
pmid: 24553386
|
3 |
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16): 1507–1517
https://doi.org/10.1056/NEJMoa1407222
pmid: 25317870
|
4 |
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385(9967): 517–528
https://doi.org/10.1016/S0140-6736(14)61403-3
pmid: 25319501
|
5 |
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood 2015; 126(2): 212–221
https://doi.org/10.1182/blood-2015-02-626754
pmid: 25979947
|
6 |
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016; 13(5): 273–290
https://doi.org/10.1038/nrclinonc.2016.25
pmid: 26977780
|
7 |
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990; 171(5): 1393–1405
https://doi.org/10.1084/jem.171.5.1393
pmid: 1692078
|
8 |
Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 1995; 25(9): 2718–2721
https://doi.org/10.1002/eji.1830250949
pmid: 7589152
|
9 |
Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, Du X, Tang L, He F. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res 2014; 74(13): 3418–3428
https://doi.org/10.1158/0008-5472.CAN-13-2690
pmid: 24769443
|
10 |
Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, Auffray C, Triebel F, Piatier-Tonneau D. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 1992; 176(2): 327–337
https://doi.org/10.1084/jem.176.2.327
pmid: 1380059
|
11 |
Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 1994; 39(3): 213–217
https://doi.org/10.1007/BF00241263
pmid: 7506235
|
12 |
Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 2002; 32(8): 2255–2263
https://doi.org/10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A
pmid: 12209638
|
13 |
Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA. Role of LAG-3 in regulatory T cells. Immunity 2004; 21(4): 503–513
https://doi.org/10.1016/j.immuni.2004.08.010
pmid: 15485628
|
14 |
Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol 2005; 35(7): 2081–2088
https://doi.org/10.1002/eji.200526090
pmid: 15971272
|
15 |
Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, Vignali DA. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 2009; 182(4): 1885–1891
https://doi.org/10.4049/jimmunol.0800185
pmid: 19201841
|
16 |
Hannier S, Triebel F. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. Int Immunol 1999; 11(11): 1745–1752
https://doi.org/10.1093/intimm/11.11.1745
pmid: 10545478
|
17 |
Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 2002; 169(10): 5392–5395
https://doi.org/10.4049/jimmunol.169.10.5392
pmid: 12421911
|
18 |
Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011; 15(1): 91–101
https://doi.org/10.1517/14712598.2011.540563
pmid: 21142803
|
19 |
Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, Yamamoto K. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci USA 2009; 106(33): 13974–13979
https://doi.org/10.1073/pnas.0906872106
pmid: 19666526
|
20 |
Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27(4): 670–684
https://doi.org/10.1016/j.immuni.2007.09.006
pmid: 17950003
|
21 |
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 2010; 107(17): 7875–7880
https://doi.org/10.1073/pnas.1003345107
pmid: 20385810
|
22 |
Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004; 172(9): 5450–5455
https://doi.org/10.4049/jimmunol.172.9.5450
pmid: 15100286
|
23 |
Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005; 115(2): 170–178
https://doi.org/10.1111/j.1365-2567.2005.02145.x
pmid: 15885122
|
24 |
Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10(1): 29–37
https://doi.org/10.1038/ni.1679
pmid: 19043418
|
25 |
Richter K, Agnellini P, Oxenius A. On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection. Int Immunol 2010; 22(1): 13–23
https://doi.org/10.1093/intimm/dxp107
pmid: 19880580
|
26 |
Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, Waldschmidt TJ, Crompton PD, Harty JT. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 2011; 13(2): 188–195
https://doi.org/10.1038/ni.2180
pmid: 22157630
|
27 |
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72(4): 917–927
https://doi.org/10.1158/0008-5472.CAN-11-1620
pmid: 22186141
|
28 |
Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190(9): 4899–4909
https://doi.org/10.4049/jimmunol.1300271
pmid: 23536636
|
29 |
Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors. Cancer Res 2016; 76(8): 2087–2093
https://doi.org/10.1158/0008-5472.CAN-15-3352
pmid: 27197251
|
30 |
Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 2017 ; 23(9): 2255–2266
pmid: 27815355
|
31 |
Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, Xia C, Wei X, Liu X, Wang H. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res 2017; 27(1): 154–157
https://doi.org/10.1038/cr.2016.142
pmid: 27910851
|
32 |
Su S, Hu B, Shao J, Shen B, Du J, Du Y, Zhou J, Yu L, Zhang L, Chen F, Sha H, Cheng L, Meng F, Zou Z, Huang X, Liu B. Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep 2017; 7: 40272
https://doi.org/10.1038/srep40272
pmid: 28102301
|
33 |
Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 2014; 42(22): e168
https://doi.org/10.1093/nar/gku936
pmid: 25300484
|
34 |
Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31(9): 827–832
https://doi.org/10.1038/nbt.2647
pmid: 23873081
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|